BRAF and neoplasm: Celecoxib (50 nM) and trametinib (25 nM) therapeutic association was tested in vitro on a simulated melanoma tumor formed of SK-MEL-28 human melanoma cells (positive for BRAF V600E and wild type NRAS mutations) and BJ human fibroblasts, used as co-culture.